What question did this study set out to answer?

This study aims to characterize molecular changes in circulating tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) during treatment.

February 28, 2026

Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer

Key Points

This study aims to characterize molecular changes in circulating tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) during treatment.
Analyzed ctDNA from patients undergoing treatment with ARPI, PARPi, and taxanes.
Monitored genetic mutations longitudinally to assess changes over time.
Evaluated associations between AR alterations and clinical outcomes.
Observed dynamic shifts in genetic mutations in response to treatments.
Found significant associations between AR alterations and patient outcomes.
Suggested potential for more personalized treatment strategies based on ctDNA analysis.

Abstract

Our study revealed dynamic shifts in genetic mutations in patients with mCRPC following ARPI, PARPi and taxanes. Furthermore, our findings highlight associations between AR alterations and clinical outcomes, emphasizing the potential for personalized treatment strategies.

Bookmark

Cite This Study

Jani et al. (Thu,) studied this question.

synapsesocial.com/papers/69a287570a974eb0d3c02f7c https://doi.org/https://doi.org/10.1158/1078-0432.ccr-25-3071

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark